Benzene-1,2,4-tricarboxylic acid;propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzene-1,2,4-tricarboxylic acid;propanoic acid
• 化学式: C12H12O8
• 分子量: 284.22
• InChiKey: BJXIAMDLGFJMPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.26
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
  申请人：XenoPort, Inc.

  公开号：US20140056973A1

  公开（公告）日：2014-02-27

  Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

  口服剂型和颗粒制剂中含有高含量的甲基氢富马酸前药。
• Pharmaceutical compositions of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20010053778A1

  公开（公告）日：2001-12-20

  Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.

  药物组合物包括一种糖原磷酸化酶抑制剂和至少一种浓度增强聚合物。该组合物可以是糖原磷酸化酶抑制剂和浓度增强聚合物的简单物理混合物，也可以是糖原磷酸化酶抑制剂和聚合物的分散体。
• Compositions comprising an HIV protease inhibitor
  申请人：Smith Wendell Scott

  公开号：US20050129772A1

  公开（公告）日：2005-06-16

  The present invention relates to pharmaceutical compositions comprising amorphous (4R)—N-allyl-3-(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, their methods of preparation, their use in inhibiting the HIV protease enzyme, and their use in treating HIV-infected mammals, such as humans.

  本发明涉及制药组合物，包括非晶态(4R)-N-烯丙基-3-(2S,3S)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-苯基丁酰}-5,5-二甲基-1,3-噻唑烷-4-羧酰胺或其药学上可接受的盐或溶剂，它们的制备方法，它们在抑制HIV蛋白酶酶中的使用以及它们在治疗HIV感染的哺乳动物，例如人类中的使用。
• Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
  申请人：Pfizer Inc

  公开号：US20040132771A1

  公开（公告）日：2004-07-08

  A composition comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor. The solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability.

  这篇文章包括(1)一个固态无定形吸附剂，其中包含一个胆固醇酯转移蛋白(CETP)抑制剂和一个底物;和(2)一个HMG-CoA还原酶抑制剂。固态无定形吸附剂相对于仅由未吸附的CETP抑制剂组成的对照组成分提供了CETP抑制剂的浓度增强，从而提高了生物利用度。
• Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
  申请人：Boyden L. Tracy

  公开号：US20070287719A1

  公开（公告）日：2007-12-13

  The invention relates to compounds of the formula or a pharmaceutically acceptable salt, prodrug or hydrates thereof. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.

  本发明涉及公式1的化合物或其药学上可接受的盐、前药或水合物。本发明还涉及包含公式1化合物的制药组合物以及通过给哺乳动物施用公式1化合物来治疗增生性疾病的方法。